Dublin, Ireland, 28th November, 2011 - ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Development Solutions division has appointed Dr. Daniel Tang as General Manager, Asia Pacific. Dr. Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with Key Opinion Leaders for early phase clinical testing.
Dr. Tang has over 15 years’ experience in drug research and brings to ICON a wealth of experience in regulated bioanalysis. Prior to joining ICON, Dr. Tang was Vice President of Operations and Bioassay/DMPK of Frontage Laboratories Inc. Prior to Frontage Laboratories, Dr. Tang was Vice President DMPK at ChemPartner Inc, where he established a bioanalytical facility in Shanghai, China. Dr. Tang also held senior scientific positions with QPS and Pfizer in the US, before returning to China in 2007. Dr. Tang obtained his PhD in Analytical Chemistry from George Washington University and his MBA from the University of Michigan.
Commenting on the appointment, Dr. Mario Rocci, President, ICON Development Solutions, said, “We are very pleased to welcome Dr. Tang to ICON. His expertise, experience and leadership will be critical as we expand our presence and range of services in the Asia Pacific region to support the growing clinical trials market there.”
Dr. Tang is an expert in regulated bioanalysis and has authored numerous research papers, conference abstracts and invited presentations, including a contribution to the 2009 industry white paper on Incurred Sample Re-analysis which later helped form industry best practices. Dr. Tang has also helped establish the first bioanalytical discussion group in Shanghai and is currently leading efforts to increase the GLP awareness and compliance of bioanalysis in the Chinese bioanalytical community. He is a steering committee member of the Global Bioanalysis Consortium, representing the Asia Pacific region.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 8,300 employees, operating from 79 locations in 38 countries. Further information is available at www.iconplc.com
Contact
Yasamin Omoomian
Weber Shandwick
+44 (0)20 7067 0594
